Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Cantor Fitzgerald
QuintilesIMS
Federal Trade Commission
McKinsey
US Department of Justice

Generated: September 15, 2019

DrugPatentWatch Database Preview

Patent: 9,388,425

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,388,425
Title:Tunable genetic switch for regulating gene expression
Abstract: The present invention relates generally the field of genetics, in particular methods, compositions and systems for controlling the inducible expression of transgenes, while eliminating background expression of transgene expression. The present invention relates to methods of use of the compositions and systems as disclosed herein for controlling the inducible expression of transgenes while eliminating background expression of transgene expression, such as use in, for example, the in generation of transgenic animals, use in therapeutic application and use in assays. In some embodiments, the present invention relates to a system of controlled expression of RNAi molecules which target binding sites in the untranslated regions of transgene, thereby the expression of the transgene is modulated and leakiness is reduced. The compositions and methods of the present invention can be used to for therapy, prophylaxis, research and diagnostics in diseases and disorders which afflict mammalian species, generation of transgenic animals, in the study of biological processes as well as for enhance performance of agricultural crops.
Inventor(s): Collins; James J (Newton Center, MA), Deans; Tara L (Clarksville, MD)
Assignee: TRUSTEES OF BOSTON UNIVERSITY (Boston, MA)
Application Number:12/446,300
Patent Claims:see list of patent claims

Details for Patent 9,388,425

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Sign Up TRUSTEES OF BOSTON UNIVERSITY (Boston, MA) 2027-10-19 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Sign Up TRUSTEES OF BOSTON UNIVERSITY (Boston, MA) 2027-10-19 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Sign Up TRUSTEES OF BOSTON UNIVERSITY (Boston, MA) 2027-10-19 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
US Department of Justice
Julphar
Cantor Fitzgerald
Deloitte
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.